Transgene SA
EPA:TNG.PA
0.87 (EUR) • At close November 8, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Transgene SA |
Symbool | TNG.PA |
Munteenheid | EUR |
Prijs | 0.871 |
Beurswaarde | 122,769,261 |
Dividendpercentage | 0% |
52-weken bereik | 0.834 - 1.528 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alessandro Riva M.D. |
Website | https://www.transgene.fr |
An error occurred while fetching data.
Over Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)